Cardeva

Cardeva (CGX-0511) is a long-acting recombinant fusion protein consisting of human B-type natriuretic peptide (BNP) fused to human serum albumin (HSA). Developed by CoGenesys (which was subsequently acquired by Teva Pharmaceutical Industries), Cardeva was designed for the chronic treatment of heart failure. By utilizing HSA fusion technology, the drug significantly extends the half-life of the native BNP peptide, which naturally has a very short duration of action. This modification allows for low-dose subcutaneous administration, potentially enabling outpatient management to improve quality of life and reduce hospitalizations for acute decompensation. Cardeva functions as an agonist at the natriuretic peptide receptor-A (NPR-A), triggering the production of cyclic GMP to induce vasodilation, natriuresis, and diuresis.

Brand names

Cardeva

Other names

HSA-BNPhuman serum albumin-B-type natriuretic peptide fusion proteinBNP-HSA